 |
|
Rattlesnake-type poisons used by superbug bacteria to beat our defenses
September 08, 2008Colonies of hospital superbugs can make poisons similar to those found in rattlesnake venom to attack our bodies' natural defences, scientists heard today (Monday 8 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
The toxins are manufactured by communities of the hospital superbug Pseudomonas aeruginosa called biofilms, which are up to a thousand times more resistant to antibiotics than free-floating single bacterial cells.
"This is the first time that anyone has successfully proved that the way the bacteria grow - either as a biofilm, or living as individuals - affects the type of proteins they can secrete, and therefore how dangerous they can potentially be to our health," says Dr Martin Welch from the University of Cambridge, UK.
"Acute diseases caused by bacteria can advance at an astonishing rate and tests have associated these types of disease with free-floating bacteria. Such free-floating bugs often secrete tissue-damaging poisons and enzymes to break down our cells, contributing to the way the disease develops, so it is natural to blame them. By contrast, chronic or long-term infections seem to be associated with biofilms, which were thought to be much less aggressive," says Dr Welch.
The research team's findings are very important to the NHS, which spends millions of pounds every year fighting chronic long-term bacterial infections which are incredibly difficult to treat.
"For example, these chronic infections by bacteria are now the major cause of death and serious disability in cystic fibrosis patients - which is the most common lethal inherited disease in the UK and affects about 8,000 people," says Dr Welch.
In cystic fibrosis the gene defect means that people are very susceptible to a particular group of opportunistic bacteria including Pseudomonas aeruginosa, which is one of the three major hospital superbugs. Aggressive antibiotic treatment can usually control the infection in cystic fibrosis sufferers but eventually the strain becomes completely resistant to antibiotics, leading to respiratory failure and death, often while still in their thirties.
"We think that the bacteria in a cystic fibrosis sufferer's lungs are partly living in communities called biofilms, and although medical scientists have investigated their strongly antibiotic-resistant properties, very little research has been done to investigate any active contribution the biofilms might have in causing diseases in the first place," says Dr Welch.
A widely-held view is that biofilms serve as reservoirs of bacteria that do relatively little harm; they just sit there. The main danger is thought to be from 'blooms' of free living cells which occasionally break away from the biofilm and cause periods of poor lung function in the cystic fibrosis patients. "In this scenario, it follows that bacteria in a biofilm will produce fewer disease-causing chemicals than free-living cells of the same type of bacteria, which is a prediction that we can test," says Dr Welch. "We found that, in contrast to expectation, biofilms do indeed produce harmful chemicals. However, the type of tissue-degrading enzymes and toxins made by the biofilm bacteria differ from those produced by free-floating bugs, which may help them to survive attacks by our immune systems."
In addition, the scientists discovered that the biofilm bacteria can produce a protein which their analysis suggests is similar to one of the active ingredients in rattlesnake venom. In the case of rattlesnake venom the protein causes the host cells to commit suicide and die, which is one reason why rattlesnake bites are so dangerous. The research team is currently studying the protein to see if it functions in the same way.
In addition the scientists have found evidence that the trigger for the bacteria to start producing these extra virulence factors is turned on very shortly after the biofilm begins to form. Once the scientists have fully identified the virulence factors created by the biofilm bacteria, the proteins and enzymes may be targeted to develop drugs for a variety of uses, including the treatment of hospital superbugs, cancer and cystic fibrosis.
Society for General Microbiology
"Acute diseases caused by bacteria can advance at an astonishing rate and tests have associated these types of disease with free-floating bacteria. Such free-floating bugs often secrete tissue-damaging poisons and enzymes to break down our cells, contributing to the way the disease develops, so it is natural to blame them. By contrast, chronic or long-term infections seem to be associated with biofilms, which were thought to be much less aggressive," says Dr Welch.
The research team's findings are very important to the NHS, which spends millions of pounds every year fighting chronic long-term bacterial infections which are incredibly difficult to treat.
"For example, these chronic infections by bacteria are now the major cause of death and serious disability in cystic fibrosis patients - which is the most common lethal inherited disease in the UK and affects about 8,000 people," says Dr Welch.
In cystic fibrosis the gene defect means that people are very susceptible to a particular group of opportunistic bacteria including Pseudomonas aeruginosa, which is one of the three major hospital superbugs. Aggressive antibiotic treatment can usually control the infection in cystic fibrosis sufferers but eventually the strain becomes completely resistant to antibiotics, leading to respiratory failure and death, often while still in their thirties.
"We think that the bacteria in a cystic fibrosis sufferer's lungs are partly living in communities called biofilms, and although medical scientists have investigated their strongly antibiotic-resistant properties, very little research has been done to investigate any active contribution the biofilms might have in causing diseases in the first place," says Dr Welch.
A widely-held view is that biofilms serve as reservoirs of bacteria that do relatively little harm; they just sit there. The main danger is thought to be from 'blooms' of free living cells which occasionally break away from the biofilm and cause periods of poor lung function in the cystic fibrosis patients. "In this scenario, it follows that bacteria in a biofilm will produce fewer disease-causing chemicals than free-living cells of the same type of bacteria, which is a prediction that we can test," says Dr Welch. "We found that, in contrast to expectation, biofilms do indeed produce harmful chemicals. However, the type of tissue-degrading enzymes and toxins made by the biofilm bacteria differ from those produced by free-floating bugs, which may help them to survive attacks by our immune systems."
In addition, the scientists discovered that the biofilm bacteria can produce a protein which their analysis suggests is similar to one of the active ingredients in rattlesnake venom. In the case of rattlesnake venom the protein causes the host cells to commit suicide and die, which is one reason why rattlesnake bites are so dangerous. The research team is currently studying the protein to see if it functions in the same way.
In addition the scientists have found evidence that the trigger for the bacteria to start producing these extra virulence factors is turned on very shortly after the biofilm begins to form. Once the scientists have fully identified the virulence factors created by the biofilm bacteria, the proteins and enzymes may be targeted to develop drugs for a variety of uses, including the treatment of hospital superbugs, cancer and cystic fibrosis.
Society for General Microbiology
Cystic Fibrosis Current Events and Cystic Fibrosis News RSSResearchers describe how cells take out the trash to prevent disease
Garbage collectors are important for removing trash; without them waste accumulates and can quickly become a health hazard. Similarly, individual cells that make up such biological organisms as humans also have sophisticated methods for managing waste.
Children with cystic fibrosis not well covered by guidelines for vitamin D needs
Existing recommendations for treating vitamin D deficiency in children with cystic fibrosis (CF) are too low to cover the serious need, leaving most at high risk for bone loss and rickets, according to researchers at Johns Hopkins Children's Center.
New approach to treating cystic fibrosis lung infection shows promise
Researchers at the University of Calgary have found a new method of fighting severe lung infections in people with cystic fibrosis (CF). These findings are published in Proceedings of the National Academy of Science USA, this week.
Protein opens hope of treatment for cystic fibrosis patients
Scientists have finally identified a direct role for the missing protein that leaves cystic fibrosis patients open to attack from lung-damaging bacteria, the main reason most of them die before their 35th birthday, scientists heard today (Thursday 11 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Clearing the airways in cystic fibrosis
By manipulating the machinery used by our cells for quality control, researchers from the University of Pittsburgh have found a way to restore the function of cystic fibrosis (CF) airway cells.
PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients with nonsense-mutation CF. The study was conducted at the Hadassah Hebrew University Hospital in Jerusalem, Israel and sponsored by PTC Therapeutics (PTC).
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
NIH scientists find a novel mechanism that controls the development of autoimmunity
Scientists at the National Institutes of Health (NIH) have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off.
Researchers discover cell's 'quality control' mechanism
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
More Cystic Fibrosis Current Events and Cystic Fibrosis News Articles
 | Cystic Fibrosis: A Guide for Patient and Family Univ. of Pittsburgh, PA. Text is designed specifically for patients with cystic fibrosis and their families. Explains the disease process, outlines the fundamentals of diagnosing and screening, and addresses the challenges of treatment for those living with CF. Includes new material on carrier testing, infection control, and more. Previous edition: c1997.... |
 | The Power of Two: A Twin Triumph over Cystic Fibrosis by Isabel Stenzel Byrnes; Anabel Stenzel The tragedy of cystic fibrosis has been touchingly recounted before, but this is the first book to portray the symbiotic relationship between twins who share this life-threatening disease through adulthood. Isabel Stenzel Byrnes and Anabel Stenzel tell of their struggle to pursue normal lives while grappling with the realization that they might die young. Their story reflects the physical and... |
 | With Every Breath: stories by and about people living with cystic fibrosis Over 30,000 people in the US have cystic fibrosis, a life-threatening genetic disease that affects the lungs and digestive system. Physically, fighting it is a very perilous struggle. Emotionally, coping can oftentimes be even harder. With Every Breath consists of stories by and about people living with cystic fibrosis. Created to motivate, inspire, and generate positivity for those living... |
 | Psychosocial Aspects of Cystic Fibrosis This work examines the psychosocial impact of the changes that have occurred in cystic fibrosis management. It includes sections on: the aetiology, pathology, course and treatment of cystic fibrosis; personal perspectives; developmental considerations; the illness network; therapeutic approaches; and major contemporary issues such as transplantation, genetic screening and new... |
 | David's Promise: A Young Man's Struggle with Cystic Fibrosis by Kathy Sykes What would it be like to navigate this life under the shadow of a deadly disease? How would you cope, both physically and psychologically? Approximately 30,000 people in our country live with the devastating illness, cystic fibrosis, and one in twenty Caucasians are carriers of its gene. Many among us are affected by CF, but few really know much about it. David's Promise delivers an in-depth... |
 | The Stones Applaud: How Cystic Fibrosis Shaped My Childhood by Teresa Anne Mullin Teresa Mullin was diagnosed with cystic fibrosis at four years of age, but it was not until she was nine that she learned most children with the disease were not expected to live to adulthood. What had been a nuisance soon became a force that molded her childhood, youth, and future. In The Stones Applaud, Mullin writes of absences from school, serving as a poster child, frequent... |
 | Cystic Fibrosis in Adults Univ. of North Carolina, Chapel Hill. Comprehensive text for the diagnosis and care of adults with cystic fibrosis. Text is organized by the organ systems most affected by CF: molecular and cellular bases of disease pathogenesis, pulmonary disease, gastrointestinal system, and other organ systems. Extensively referenced. DNLM: Cystic Fibrosis--in... |
 | Cystic Fibrosis: Everything You Need To Know (Your Personal Health) by Wayne Kepron Cystic fibrosis afflicts approximately 30,000 Americans. The average age of survival has been steadily increasing, but not quickly enough: a child born with cystic fibrosis today can only expect to live 35 to 40 years. In this valuable new addition to the Your Personal Health series, Dr. Wayne Kepron offers a comprehensive look at the disease that afflicts so many young people. Topics... |
 | Cystic Fibrosis by Margaret Hodson, Duncan Geddes, Andrew Bush This international and authoritative work, which brings together current knowledge in the field of cystic fibrosis, has become established in previous editions as a leading reference in the field. The third edition continues to provide everything that the clinician or allied health professional treating patients with cystic fibrosis will need in a single manageable volume. Thoroughly revised... |
 | Treatment of the Hospitalized Cystic Fibrosis Patient (Lung Biology in Health and Disease) This up-to-the-minute single-source reference provides a complete overview of cystic fibrosis (CF) care for the hospitalized patient, assisting in the successful development of effective management approaches to many of the serious symptoms and complications associated with both the disease and its related long-term treatment effects. Detailing the general principles for inpatient therapy,... |
| © 2008 BrightSurf.com |